Obstructive hypertrophic cardiomyopathy

Article written and reviewed by Dr Luca Moretti

Obstructive hypertrophic cardiomyopathy is the form in which left ventricular ejection encounters a dynamic narrowing, generally in the outflow tract, produced by the interaction among the septum, flow and the mitral apparatus. A peak instantaneous gradient of at least 30 mmHg, present at rest or physiologically provoked, defines obstruction; a value of at least 50 mmHg becomes relevant to therapeutic decisions when symptoms are attributable to the mechanism. The two numbers therefore answer different questions and should not be interchanged.

Obstruction is not a fixed stenosis like a calcified valve. It varies with preload, afterload, contractility, heart rate, posture, temperature, meals, alcohol and medications, so that the same patient may have very different gradients on the same day. This hemodynamic lability explains why a normal resting examination does not exclude the obstructive form and why an isolated measurement does not always quantify the daily burden. Symptoms and gradient must be correlated under conditions that reproduce real life.

Systolic anterior motion of the mitral valve, or SAM, is the most common mechanism but does not arise solely from a thick septum. Elongated leaflets, anteriorly positioned papillary muscles, abnormal chordae, a small cavity and an unfavorable angle between the septum and aorta modify the flow path. The valve is pushed and drawn toward the septum during systole, progressively narrowing the tract. Mitral SAM is therefore the expression of a ventricular-valvular complex rather than of a single structure.

Part of the elevated ventricular pressure is dissipated across the gradient, while mitral-septal contact produces mitral regurgitation, often directed posteriorly. The ventricle sustains greater stress, filling is already limited by stiffness, and the left atrium receives both high diastolic pressures and regurgitant volume. Dyspnea, pain, presyncope and reduced functional capacity may result from this combination. Obstructive pathophysiology therefore includes pressure, valve function, ischemia and filling, not only the Doppler value.

The obstructive form must be distinguished from midventricular obstruction, aortic stenosis and transient dynamic gradients in people without HCM. A hypovolemic, hypercontractile ventricle may develop SAM in sepsis or after surgery; a sigmoid septum in an older person may generate a gradient without the same familial architecture. Diagnosis requires the HCM phenotype to be defined and the site of narrowing to be precisely localized. This distinction determines medications and procedures.

Functional anatomy and gradient formation

The outflow tract is a three-dimensional space bounded by the septum, mitral valve and subvalvular structures. Basal hypertrophy reduces the available cross-sectional area, but septal shape and orientation may be as important as maximal thickness. A convex septum protrudes into the flow and brings the mitral valve closer, whereas a very thick segment away from the tract may not produce obstruction. Planning should therefore be based on multiplanar geometry rather than an isolated parasternal measurement.

The mitral leaflets are often longer than in the general population and may extend beyond the coaptation point. Anteriorly positioned papillary muscles or direct insertions into the leaflet shift the apparatus toward the tract; accessory muscles and fibrotic chordae further modify motion. These abnormalities explain severe obstruction even with moderate hypertrophy. The subvalvular apparatus must be mapped before myectomy because septal resection alone may not resolve a valve-dominant mechanism.

During ejection, flow accelerates and interacts with the posterior surface of the anterior leaflet. Drag force, more than simple Venturi suction, pushes the mitral valve toward the septum and prolongs contact. Progressive narrowing produces the late-peaking, dagger-shaped Doppler profile. The positive feedback between acceleration and SAM explains the rapid amplification of the gradient once a critical geometry is reached.

Regurgitation secondary to SAM results from incomplete coaptation and tends to be directed posteriorly. A central or anterior jet, calcification, prolapse or chordal rupture suggests primary or additional mitral disease. Its severity varies with the gradient and may decrease when obstruction is corrected. Characterization of regurgitation avoids unnecessary valve replacement or, conversely, failure to correct a true organic lesion.

Reduction in end-diastolic volume brings the septum and mitral valve closer together. Dehydration, intense diuresis, bleeding, vasodilation, fever and standing may therefore accentuate the gradient; large meals redistribute blood flow and some patients worsen in the postprandial period. Increased contractility during stress or catecholamine exposure further accelerates flow. Load dependence does not mean the symptom is psychogenic, but that the mechanism is sensitive to physiological conditions.

Obstruction increases intraventricular systolic pressure and oxygen consumption, while effective aortic pressure may fail to rise adequately during exercise. The combination promotes ischemia, an abnormal blood pressure response and presyncope. The pulse may show a brisk initial upstroke followed by collapse and a second wave, but this sign is not constant. Cardiac output reserve may be reduced even with an apparently high ejection fraction.

The gradient does not correspond to the overall severity of HCM. Fibrosis, microvascular dysfunction, chronotropic incompetence and fibrillation may produce major symptoms even after effective gradient reduction. Conversely, some people with a high gradient report little limitation. Correlation between mechanism and symptom is essential before intensifying therapy because a septal procedure does not correct lung disease or anemia.

Over time, high pressures, regurgitation and stiffness promote atrial dilation and fibrillation. Scar may increase because of ischemia and stress, but not every patient follows this trajectory. Early symptom control does not necessarily demonstrate modification of the biological substrate. The natural history remains that of HCM and requires arrhythmic and family surveillance even when the gradient disappears after treatment.

The gradient may appear after meals because of splanchnic vasodilation and volume redistribution, causing limitation that is not reproduced in the fasting morning state. A diary linking symptoms, meals, heat and activity may guide the exercise protocol. It is not necessary to pursue every fluctuation with an examination, but the usual context must be understood. The daily burden is often better represented by a careful history than by the maximum gradient provoked under artificial conditions.

Elevated ventricular pressure may contribute to subendocardial ischemia and increased natriuretic peptides, but these markers do not directly measure obstruction. Elevated troponin requires exclusion of an acute coronary syndrome when clinically plausible. Myocardial injury reflects the interaction among pressure, microcirculation and demand and should not be used as an isolated criterion for a septal procedure.

Diagnosis, provocation and symptom attribution

Resting echocardiography defines morphology, SAM, mitral-septal contact, regurgitation and gradient. Continuous-wave Doppler should be aligned with the jet and sampled from multiple windows, avoiding confusion with the mitral regurgitation signal, which is generally earlier and faster. Envelope shape and correlation with color Doppler aid distinction. An accurate measurement requires reporting hemodynamic conditions, blood pressure and rhythm at the time of examination.

If the resting gradient is below 50 mmHg, Valsalva and rapid standing may reveal a latent component. The maneuver must be effective and the signal acquired at the appropriate time; a weak Valsalva is not equivalent to a negative test. Nitrates may be used in some laboratories, but exercise better reproduces the physiology of symptoms. Provocation is a structured part of the examination, not an optional add-on.

Exercise echocardiography is indicated when symptoms and baseline data are discordant or when a provocable gradient must be documented. A treadmill followed by immediate imaging may miss rapid changes during recovery; a semisupine bicycle allows imaging during effort but changes posture and loading. The protocol should report the timing of peak and recovery. Temporal correlation among dyspnea, blood pressure, gradient and regurgitation is more informative than the isolated maximum value.

Dobutamine artificially increases contractility and may induce gradients that do not represent everyday activities, so it is not the standard mode of provocation. A gradient detected only after an extrasystole should also be interpreted cautiously because the postextrasystolic beat has distinctive filling and contractility. The objective is not to prove that the ventricle can obstruct under any extreme circumstance. A clinically relevant obstruction that is reproducible must be identified.

Magnetic resonance measures the septum, mitral valve, papillary muscles and scar when echocardiography is incomplete. Flow can be visualized, but echocardiography remains more practical for dynamics and provocation. Computed tomography is useful for coronary anatomy, mitral calcium or planning in selected cases. Multimodality imaging should answer specific problems, such as anomalous papillary insertion or a wall segment not visualized.

Simultaneous catheterization of the left ventricle and aorta is reserved for important discrepancies or invasive planning. The pressure curve localizes the gradient and distinguishes outflow tract, midcavity and valvular stenosis. The Brockenbrough-Braunwald-Morrow phenomenon after an extrasystole demonstrates the dynamic nature but is unnecessary in most cases. Invasive hemodynamics complements rather than replaces a well-performed noninvasive assessment.

Dyspnea and pain require investigation for fibrillation, epicardial ischemia, anemia, obesity, deconditioning and lung disease. An inadequate blood pressure response or exercise-induced arrhythmias may explain presyncope independently of the maximum gradient. Cardiopulmonary exercise testing quantifies limitation and may show ventilatory inefficiency or reduced output. Symptom attribution is decisive because the effectiveness of drugs and procedures depends on the correct target being present.

The differential diagnosis includes aortic stenosis, subaortic membrane, mitral apparatus abnormalities, hypovolemia and stress cardiomyopathy with SAM. A high velocity at the midventricular level should not be called LVOTO without localization. In older patients, aortic stenosis and obstructive HCM may coexist, requiring separation of the components. Double obstruction makes a decision based on aggregate Doppler velocity alone dangerous.

Ambulatory monitoring of blood pressure and heart rate may clarify episodes related to hypotension or tachycardia but does not directly measure the gradient. Wearable devices document rhythm and activity with variable quality, and their signals should be confirmed before major decisions. Symptom-rhythm correlation prevents palpitations due to fibrillation or ectopy from being attributed to the gradient.

Three-dimensional transesophageal echocardiography is used when mitral and papillary anatomy remain uncertain or during surgery. It shows coaptation, insertions and regurgitation and immediately verifies the result of myectomy. It is not a screening examination. Intraoperative assessment makes it possible to recognize a residual gradient and correct an unresolved mechanism before completing the operation.

Drug therapy and myosin inhibitors

Initial therapy corrects factors that accentuate the gradient and uses drugs capable of prolonging filling or reducing hypercontractility. Hydration should be adequate without causing congestion; fever, anemia and tachyarrhythmias are treated. Pure vasodilators and excessive doses of diuretics may worsen obstruction in some patients, but there is no universally prohibited list independent of context. Preload management requires a balance between a small cavity and high filling pressures.

Nonvasodilating beta-blockers are a frequent first choice. They reduce heart rate, prolong diastole and attenuate the adrenergic increase in contractility, with benefit especially during exercise. Dose is titrated according to symptoms, blood pressure, bradycardia and chronotropic capacity, not to reach a fixed value. Clinical benefit may occur without abolishing the gradient and should be verified during activities that previously caused limitation.

Verapamil and diltiazem improve relaxation and rate control in some patients, but the vasodilating effect may be unfavorable with hypotension or a very high gradient. Severe congestion and low blood pressure require particular caution. Indiscriminate combination with a beta-blocker increases the risk of bradycardia and block. Calcium-channel blockers are not equivalent to dihydropyridines, which are not a treatment for obstruction and may reduce afterload.

Disopyramide has a marked negative inotropic effect and may be added when initial drugs do not control obstruction. QT interval, renal function, glaucoma, urinary retention and other anticholinergic effects influence its use; it is often combined with a drug that controls atrioventricular conduction. Initiation requires appropriate safety protocols. Pharmacologic reduction of the gradient does not remove the need to monitor rhythm and progression.

Mavacamten stabilizes a proportion of myosin in a state less available for contraction and reduces hypercontractility. EXPLORER-HCM demonstrated improvements in capacity, functional class and gradient; VALOR-HCM reduced the proportion of patients who remained eligible for or chose septal reduction therapy during the study period. The therapeutic window requires echocardiography and attention to metabolic interactions. A reduced ejection fraction requires interruption or adjustment according to the prescribing information because the pharmacologic effect may become excessive.

Aficamten is another selective myosin inhibitor with different pharmacokinetic characteristics. In SEQUOIA-HCM it improved peak oxygen consumption, symptoms and gradient compared with placebo; since 2026 it has European authorization for adults with symptomatic obstructive HCM. Availability of two molecules does not allow doses or protocols to be transferred from one to the other. Drug-specific monitoring must follow updated regulatory information, including ventricular function, concomitant medications and reproductive risk.

Myosin inhibitors are not a mandatory alternative to myectomy for every patient. Age, anatomy, preferences, access to monitoring, polypharmacy, pregnancy plans and the presence of a mitral lesion modify the choice. Chronic treatment avoids a procedure but requires continuity and surveillance; surgery offers durable anatomic correction with perioperative risk. Shared decision-making should compare real options rather than present one pathway as universally superior.

Response is assessed by capacity, functional class, KCCQ, gradient, regurgitation, natriuretic peptides and safety. A numerical reduction without perceived benefit should prompt a search for other mechanisms, whereas symptomatic improvement with a residual gradient may be clinically valid. Antiarrhythmic drugs, anticoagulation and treatment of comorbidities remain independent. The therapeutic endpoint is the patient's health, not cosmetic normalization of a Doppler tracing.

Drug interactions are particularly important with myosin inhibitors because enzyme modifiers may increase or reduce exposure. Every new antibiotic, antifungal, antiarrhythmic or over-the-counter product should be checked against the prescribing information of the molecule being used. Medication reconciliation is part of monitoring and should involve the prescriber, pharmacist and HCM center.

Stopping a myosin inhibitor may allow the gradient to recur, whereas temporary interruption is necessary under defined conditions of dysfunction or interaction. The patient should know the plan without changing the dose independently. Chronic treatment requires an organization capable of ensuring echocardiography, continuity and rapid response to clinical changes.

Myectomy, alcohol ablation and choice of procedure

Septal reduction therapy is considered when severe symptoms, generally NYHA class III or IV or equivalent limitation, are attributable to a gradient of at least 50 mmHg despite adequate treatment. Some patients with exertional syncope or less advanced but important symptoms may be assessed individually. The indication requires confirmation of the mechanism and discussion at an expert HCM center. Operating on an asymptomatic patient solely to prevent hypothetical progression is not standard practice.

Transaortic myectomy removes a portion of the basal and midseptum, widens the tract and interrupts SAM. The extent is adapted to the site of contact and anatomy; a resection that is too short leaves a gradient, whereas excessive resection increases the risk of septal defect or block. The surgeon may mobilize papillary muscles, divide abnormal connections or correct an organic valve lesion. Extended myectomy is therefore a personalized anatomic reconstruction, not a simple standardized excision.

At high-volume centers, perioperative mortality and residual gradient are low and symptomatic improvement is durable. Complications include atrioventricular block, septal defect, aortic regurgitation, bleeding and persistent regurgitation; risk increases with limited experience and complex anatomy. Left bundle branch block is common after surgery and becomes relevant if right bundle branch block preexists. Center volume is a clinical component of the choice and not an organizational detail.

Alcohol ablation injects a small amount of ethanol into a septal branch supplying the contact area, producing a controlled infarction and subsequent thinning. Intracoronary contrast echocardiography verifies the territory before injection because inappropriate distribution may injure papillary muscles or the right ventricle. The full effect requires remodeling over time. Coronary anatomy determines feasibility and cannot be compensated for by indiscriminately increasing the alcohol dose.

Atrioventricular block requiring a pacemaker is a characteristic complication of ablation, together with unintended infarction, arrhythmias, dissection and residual gradient. Preexisting left bundle branch block increases the risk of complete block after injury to the right-sided conduction system. The created scar is theoretically arrhythmogenic, although overall outcomes at expert centers are favorable in selected patients. Electrical selection should accompany anatomic selection.

Surgery is generally favored in younger patients, with very marked hypertrophy, mitral or papillary abnormalities, another required cardiac operation or anatomy unsuitable for alcohol. Ablation may be preferred in older people with comorbidities or greater surgical risk and an appropriate septal branch. These are not absolute rules and informed preferences matter. The individual comparison should include the probability of pacemaker implantation, reintervention, recovery and expected outcome at the available center.

Dual-chamber pacing with a short atrioventricular interval may reduce the gradient in some patients, but the average effect on symptoms is smaller and more variable than with septal strategies. It has a role mainly when a pacing indication already exists or other options are not feasible. Response should not be assumed from an acute reduction. Ventricular pacing is not a universal substitute for myectomy.

After the procedure, resting and provoked gradients, regurgitation, conduction, function and symptoms are assessed. A residual gradient may result from insufficient resection, a mitral abnormality, a midventricular site or incorrect measurement. Persistent dyspnea with an abolished gradient requires consideration of stiffness, ischemia, fibrillation, deconditioning and comorbidities. Postprocedural follow-up retains arrhythmic and family risk stratification because septal reduction does not erase the cardiomyopathy.

The presence of coronary artery disease may require concomitant bypass at the time of myectomy, whereas aortic stenosis or organic mitral disease modifies the operation. The plan should avoid fragmented procedures when a single expert operation can treat multiple targets. Combined cardiac surgery increases complexity and requires assessment of overall benefit rather than the simple sum of separate indications.

An ineffective procedure should not be repeated without redefining the mechanism. Residual midventricular obstruction, an abnormal valve or scar may explain apparent failure. Magnetic resonance, transesophageal imaging and review of the initial images precede a new strategy. Reintervention requires even greater expertise because conduction and anatomy have already been altered.

Complications, special situations and prognosis

Acute hypotension with severe obstruction requires a logic opposite to that of shock from pure systolic dysfunction. Cautious filling, reduction of tachycardia and vasoconstriction with appropriate agents may improve geometry, whereas inotropes and vasodilators may worsen the gradient. Bedside echocardiography rapidly clarifies the mechanism. Obstructive shock must be recognized because an unadapted standard therapy may cause immediate deterioration.

During pregnancy, increased volume may attenuate the gradient, but tachycardia and reduced vascular resistance may accentuate it; labor, hemorrhage and the postpartum period are delicate transitions. Medications and myosin inhibitors require preconception review. Analgesia, maintenance of venous return and prevention of abrupt changes are central principles. The obstetric plan is developed with an expert team rather than based on the isolated gradient.

Atrial fibrillation may precipitate congestion because it shortens filling and eliminates atrial contraction. Early cardioversion is often useful when instability is attributable to the rhythm, together with anticoagulation and a strategy to prevent recurrence. Rate should be controlled without excessive vasodilation or bradycardia. Atrial rhythm is part of obstructive hemodynamics and not a separate complication to be treated only according to general algorithms.

Sudden death is not explained by the gradient alone. Obstruction and pressure may contribute to the substrate, but the ICD decision integrates family history, syncope, wall thickness, function, aneurysm, NSVT and LGE. Effective septal reduction does not automatically justify removing an ICD or abandoning surveillance. Arrhythmic risk belongs to HCM as a whole and should be reassessed independently of hemodynamic success.

Infective endocarditis does not require routine antibiotic prophylaxis for obstructive HCM alone according to contemporary recommendations; prophylaxis follows the high-risk cardiac categories defined by guidelines. Previous endocarditis or prosthetic material may change the situation. Oral hygiene and prompt assessment of fever remain important. This distinction avoids unnecessary antibiotics without neglecting patients with a real indication.

Physical activity should be personalized. Dehydration, heat and explosive exertion may accentuate the gradient, but universal sedentary behavior is not justified and worsens capacity and metabolic factors. Prescription considers symptoms, blood pressure response, arrhythmias and the possibility of hydration and supervision. A progressive, shared exercise program is more useful than generic prohibitions based solely on the term obstructive.

Prognosis after effective therapy is generally favorable, especially when the procedure is performed at expert centers before advanced remodeling. Atrial fibrillation, scar, pulmonary hypertension and dysfunction may nevertheless persist and determine events independently of the gradient. Clinical response should be assessed over the long term. Hemodynamic success is one component of care, not a synonym for cure.

The choice between chronic therapy and intervention evolves with new data, availability and preferences. Myosin inhibitors have expanded the alternatives but require monitoring and safety information; surgery and ablation have decades of experience and center-dependent outcomes. The patient should be able to revisit the decision when symptoms, anatomy or personal circumstances change. A dynamic strategy preserves all options and measures outcomes in everyday life.

During the perioperative period of noncardiac surgery, fasting, anesthesia and bleeding may accentuate obstruction. The team maintains venous return and afterload, avoids tachycardia and has echocardiography available if instability occurs. Anesthetic preparation is proportional to the gradient, symptoms and procedural complexity and does not automatically require postponement of necessary surgery.

Prognosis should be reassessed even after dramatic symptomatic improvement. Fibrillation, scar, aneurysm and family history continue to follow independent trajectories, while a more active patient may reveal new limitations. Long-term success includes maintaining capacity and preventing complications, not merely the gradient measured at discharge.